Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (Weighted Average) (2016 - 2026)

Summit Therapeutics filings provide 13 years of Shares Outstanding (Weighted Average) readings, the most recent being $775.5 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 5.06% to $775.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $775.5 million through Mar 2026, up 5.06% year-over-year, with the annual reading at $747.7 million for FY2025, 4.06% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $775.5 million in Q1 2026 for Summit Therapeutics, up from $741.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $775.5 million in Q1 2026 and bottomed at $140.0 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $556.9 million, with a median of $699.8 million recorded in 2023.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 398.07% in 2023 before it increased 1.03% in 2024.
  • Summit Therapeutics' Shares Outstanding (Weighted Average) stood at $193.3 million in 2022, then soared by 220.5% to $619.6 million in 2023, then grew by 15.96% to $718.5 million in 2024, then grew by 3.18% to $741.4 million in 2025, then rose by 4.6% to $775.5 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Shares Outstanding (Weighted Average) are $775.5 million (Q1 2026), $741.4 million (Q3 2025), and $742.6 million (Q2 2025).